EP1685151A4 - Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux - Google Patents

Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux

Info

Publication number
EP1685151A4
EP1685151A4 EP04800514A EP04800514A EP1685151A4 EP 1685151 A4 EP1685151 A4 EP 1685151A4 EP 04800514 A EP04800514 A EP 04800514A EP 04800514 A EP04800514 A EP 04800514A EP 1685151 A4 EP1685151 A4 EP 1685151A4
Authority
EP
European Patent Office
Prior art keywords
peptides
treatment
methods
brain disorders
neuronal regeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04800514A
Other languages
German (de)
English (en)
Other versions
EP1685151A2 (fr
Inventor
Frank Sieg
Thorsten Gorba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuren Pharmaceuticals Ltd
Original Assignee
NEUREN PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUREN PHARMACEUTICALS Ltd filed Critical NEUREN PHARMACEUTICALS Ltd
Publication of EP1685151A2 publication Critical patent/EP1685151A2/fr
Publication of EP1685151A4 publication Critical patent/EP1685151A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
EP04800514A 2003-10-31 2004-11-01 Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux Withdrawn EP1685151A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51601803P 2003-10-31 2003-10-31
US58504104P 2004-07-02 2004-07-02
US61627104P 2004-10-05 2004-10-05
PCT/US2004/036203 WO2005042561A2 (fr) 2003-10-31 2004-11-01 Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux

Publications (2)

Publication Number Publication Date
EP1685151A2 EP1685151A2 (fr) 2006-08-02
EP1685151A4 true EP1685151A4 (fr) 2009-04-22

Family

ID=34557374

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04800514A Withdrawn EP1685151A4 (fr) 2003-10-31 2004-11-01 Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux

Country Status (3)

Country Link
EP (1) EP1685151A4 (fr)
JP (1) JP5026083B2 (fr)
WO (1) WO2005042561A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4988711B2 (ja) * 2005-05-06 2012-08-01 クロンズ ホールディングズ カンパニー リミテッド 神経再生ペプチド及びそれを含む処方物
WO2007011595A2 (fr) * 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Peptides de regeneration neurale et antioxydants protegeant les neurones de la degenerescence
JP2009513689A (ja) * 2005-10-31 2009-04-02 ラボラトワール セローノ ソシエテ アノニム 神経学的疾患の治療、及び／又は予防のためのｓｄｆ−１の使用
WO2009051844A1 (fr) 2007-10-17 2009-04-23 Neuren Pharmaceuticals Limited Analogues synthétiques de peptides de régénération neurale
WO2013112002A1 (fr) * 2012-01-27 2013-08-01 의료법인 성광의료재단 Biomarqueur destiné à réduire ou soulager des symptômes de lésion cérébrale
JP6370779B2 (ja) * 2012-07-27 2018-08-08 クロンズ ホールディングズ カンパニー リミテッドＣｕｒｏｎｚ Ｈｏｌｄｉｎｇｓ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 眼虚血または眼の再灌流傷害を治療または予防する医薬
US20160031937A1 (en) * 2013-03-08 2016-02-04 Curonz Holdings Company Limited Neural regeneration peptides and uses therefor
KR20160065969A (ko) * 2013-10-11 2016-06-09 타릭스 파마슈티컬스 엘티디. 신규 펩티드 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018754A2 (fr) * 2001-08-24 2003-03-06 Neuronz Limited Peptides de regeneration neurale et procedes d'utilisation de ces derniers dans le traitement des lesions cerebrales

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721464A4 (fr) * 1993-09-01 1998-12-30 Start Technology Partnership Facteur regulateur de neurones servant a promouvoir la survie des neurones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018754A2 (fr) * 2001-08-24 2003-03-06 Neuronz Limited Peptides de regeneration neurale et procedes d'utilisation de ces derniers dans le traitement des lesions cerebrales

Also Published As

Publication number Publication date
WO2005042561A2 (fr) 2005-05-12
WO2005042561A3 (fr) 2006-10-12
EP1685151A2 (fr) 2006-08-02
JP5026083B2 (ja) 2012-09-12
JP2007511210A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
MA29084B1 (fr) Derives d'indenyle et leur utilisation dans le traitement de troubles neurologiques
EP1727567A4 (fr) Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies a un complement
EP1799269A4 (fr) Oligoribonucléotides et procédés d'utilisation associés pour le traitement de l'alopécie, des insuffisances rénales aiguës et d'autres maladies
FR2869541B1 (fr) Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee
EP2173740A4 (fr) Inhibiteurs de l'hème-oxygénase et leur utilisation dans le traitement du cancer et de maladies du système nerveux central
IL174918A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EP1670427A4 (fr) Procedes et reactifs pour le traitement des troubles immuno-inflammatoires
EP1781303A4 (fr) Procedes et reactifs pour le traitement de troubles metaboliques
EP1569636A4 (fr) Utilisation d'equol dans le traitement de maladies d'origine androgenique
EP1366012A4 (fr) Acides 2-aryloxy-2-arylalcano ques utilis s pour le traitement du diab tes et des troubles lipidiques
EP1495130A4 (fr) Utilisation de cibles biomoleculaires dans le traitement et la visualisation de tumeurs cerebrales
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
EP1680009A4 (fr) Compositions et procedes pour le diagnostic et de traitement de troubles mentaux
EP1626728A4 (fr) Lipides oxydes et leur utilisation dans le traitement de maladies et de troubles inflammatoires
AU2003284968A8 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
EP1644039A4 (fr) Compositions et procedes pour le traitement des troubles lies a la coagulation
DE69603456D1 (de) Vorrichtung zur kontrolle von biologischen/medizinischen flüssigkeitsströmen zum und vom patienten
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
MA27381A1 (fr) Association synergique d'un ligand de alpha-2-delta et d'un inhibiteur de pdev pour une utilisation dans le traitement de la douleur
EP1711197A4 (fr) Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
NO20033443D0 (no) Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser
EP1292279A4 (fr) Utilisation d'acetate de glatiramere (copolymere 1) pour traiter des maladies du systeme nerveux central
EP1572887A4 (fr) Peptides de regeneration neurale et procedes d'utilisation de ces derniers dans le traitement des lesions cerebrales
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
EP1685151A4 (fr) Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060526

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK YU

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 1/00 20060101ALI20061125BHEP

Ipc: A01N 37/18 20060101ALI20061125BHEP

Ipc: A01N 61/00 20060101AFI20061125BHEP

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUREN PHARMACEUTICALS LIMITED

A4 Supplementary search report drawn up and despatched

Effective date: 20090319

17Q First examination report despatched

Effective date: 20100121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121030